Literature DB >> 33327546

Clinical Profile, Treatment and Predictors during the First COVID-19 Wave: A Population-Based Registry Analysis from Castile and Leon Hospitals.

Eduardo Gutiérrez-Abejón1,2, Eduardo Tamayo3,4,5, Débora Martín-García6, F Javier Álvarez1,3,7, Francisco Herrera-Gómez1,3,8.   

Abstract

The first wave of the COVID-19 pandemic collapsed the hospitals in Castile and Leon (Spain). An analysis of the clinical characteristics, drug therapies and principal outcome predictors in the COVID-19 hospitalized patients from 1 March to 31 May 2020 is presented through a population-based registry study. Hospital stay variables, ventilation mode data and clinical outcomes were observed. In Castile and Leon hospitals, 7307 COVID-19 patients were admitted, with 57.05% being male and a median of 76 years. The mortality rate was 24.43%, with a high incidence of severe acute respiratory syndrome (SARS) (14.03%) and acute kidney injury (AKI) (10.87%). The most used medicines were antibiotics (90.83%), antimalarials (42.63%), steroids (44.37%) and antivirals, such as lopinavir/ritonavir (42.63%). The use of tocilizumab (9.37%) and anti-SIRS (systemic inflammatory response syndrome) medicines (7.34%) were remarkable. Fundamentally, death occurred more likely over 65 years of age (OR: 9.05). In addition, the need for ventilation was associated with a higher probability of death (OR: 3.59), SARS (OR: 5.14) and AKI (OR: 2.31). The drug-use pattern had been modified throughout the COVID-19 first wave. Multiple factors, such as age, gender and the need for mechanical ventilation, were related to the worst evolution prognosis of the disease.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; acute kidney injury; clinical characteristics; mortality; severe acute respiratory syndrome; treatment

Year:  2020        PMID: 33327546     DOI: 10.3390/ijerph17249360

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  4 in total

1.  Hospitalized COVID-19 Patients with Severe Acute Respiratory Syndrome: A Population-Based Registry Analysis to Assess Clinical Findings, Pharmacological Treatment and Survival.

Authors:  Eduardo Gutiérrez-Abejón; Francisco Herrera-Gómez; M Aránzazu Pedrosa-Naudín; Eduardo Tamayo; F Javier Álvarez
Journal:  Medicina (Kaunas)       Date:  2022-06-19       Impact factor: 2.948

2.  A Population-Based Registry Analysis on Hospitalized COVID-19 Patients with Previous Cardiovascular Disease: Clinical Profile, Treatment, and Predictors of Death.

Authors:  Eduardo Gutiérrez-Abejón; Francisco Herrera-Gómez; Débora Martín-García; Eduardo Tamayo; Francisco Javier Álvarez
Journal:  J Cardiovasc Dev Dis       Date:  2021-11-29

3.  Sex Differences and Predictors of In-Hospital Mortality among Patients with COVID-19: Results from the ANCOHVID Multicentre Study.

Authors:  Nicolás Francisco Fernández-Martínez; Rocío Ortiz-González-Serna; Álvaro Serrano-Ortiz; Mario Rivera-Izquierdo; Rafael Ruiz-Montero; Marina Pérez-Contreras; Inmaculada Guerrero-Fernández de Alba; Álvaro Romero-Duarte; Inmaculada Salcedo-Leal
Journal:  Int J Environ Res Public Health       Date:  2021-08-26       Impact factor: 3.390

4.  Diphtheria And Tetanus Vaccination History Is Associated With Lower Odds of COVID-19 Hospitalization.

Authors:  Jennifer Monereo-Sánchez; Jurjen J Luykx; Justo Pinzón-Espinosa; Geneviève Richard; Ehsan Motazedi; Lars T Westlye; Ole A Andreassen; Dennis van der Meer
Journal:  Front Immunol       Date:  2021-10-07       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.